Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( <scp>HR</scp> +/ <scp>HER2</scp> −) Advanced Breast Cancer Treated With Palbociclib in the <scp>POLARIS</scp> Study

Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi, Steven McCune, Sobha Kurian, Mehdi M. Moezi, Daniel M. Anderson, Yan Ji, Timothy J. Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z. Montelongo, Zhe Zhang, Joseph C. Cappelleri, Eric Gauthier, Gabrielle B. Rocque

Open source

DOI
10.1002/cam4.71788
Published
2026-04
Container
Cancer Medicine
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cam4.71788,
  title = {Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative (
                    <scp>HR</scp>
                    +/
                    <scp>HER2</scp>
                    −) Advanced Breast Cancer Treated With Palbociclib in the
                    <scp>POLARIS</scp>
                    Study},
  author = {Debu Tripathy and Joanne L. Blum and Meghan S. Karuturi and Steven McCune and Sobha Kurian and Mehdi M. Moezi and Daniel M. Anderson and Yan Ji and Timothy J. Pluard and John Migas and Shailendra Lakhanpal and Erin Jepsen and Yao Wang and Monica Z. Montelongo and Zhe Zhang and Joseph C. Cappelleri and Eric Gauthier and Gabrielle B. Rocque},
  year = {2026},
  journal = {Cancer Medicine},
  doi = {10.1002/cam4.71788},
  url = {https://doi.org/10.1002/cam4.71788}
}

RIS

TY  - JOUR
TI  - Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative (
                    <scp>HR</scp>
                    +/
                    <scp>HER2</scp>
                    −) Advanced Breast Cancer Treated With Palbociclib in the
                    <scp>POLARIS</scp>
                    Study
AU  - Debu Tripathy
AU  - Joanne L. Blum
AU  - Meghan S. Karuturi
AU  - Steven McCune
AU  - Sobha Kurian
AU  - Mehdi M. Moezi
AU  - Daniel M. Anderson
AU  - Yan Ji
AU  - Timothy J. Pluard
AU  - John Migas
AU  - Shailendra Lakhanpal
AU  - Erin Jepsen
AU  - Yao Wang
AU  - Monica Z. Montelongo
AU  - Zhe Zhang
AU  - Joseph C. Cappelleri
AU  - Eric Gauthier
AU  - Gabrielle B. Rocque
PY  - 2026
JO  - Cancer Medicine
DO  - 10.1002/cam4.71788
UR  - https://doi.org/10.1002/cam4.71788
ER  - 

APA

Tripathy, D., Blum, J. L., Karuturi, M. S., McCune, S., Kurian, S., Moezi, M. M., Anderson, D. M., Ji, Y., Pluard, T. J., Migas, J., Lakhanpal, S., Jepsen, E., Wang, Y., Montelongo, M. Z., Zhang, Z., Cappelleri, J. C., Gauthier, E., & Rocque, G. B. (2026). Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( <scp>HR</scp> +/ <scp>HER2</scp> −) Advanced Breast Cancer Treated With Palbociclib in the <scp>POLARIS</scp> Study. Cancer Medicine. https://doi.org/10.1002/cam4.71788

Source records